Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546740 | 0.80 | LPL (0.41) | GRM5 | |
| SCHEMBL1306384 | 0.76 | GABRA1 (0.38) | GRM5 | |
| SCHEMBL15704217 | 0.75 | — | — | |
| SCHEMBL1306505 | 0.74 | APP (0.41) | GRM5 | |
| SCHEMBL1478000 | 0.71 | LOX (0.35) | — | |
| SCHEMBL12829544 | 0.70 | — | — | |
| SCHEMBL2854252 | 0.70 | CYP1A1 (0.44) | GRM5 | |
| SCHEMBL4189891 | 0.70 | CTRC (0.35) | — | |
| SCHEMBL9851138 | 0.69 | — | — | |
| SCHEMBL19174201 | 0.68 | CYP1A1 (0.48) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BOARD INSTITUTE, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-8815903-B2 | Indole derivative and pharmacologically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-2185564-B1 | Herbicidally active cyclopentanedione compounds and derivatives thereof | SYNGENTA LTD (GB) | 2014-06-18 | — | — | EP | disclosed |
| US-8754242-B2 | Herbicides | SYNGENTA CROP PROTECTION LLC (US) | 2014-06-17 | — | — | US | disclosed |
| CN-101855225-B | Tricyclic bridged cyclopentanedione derivatives as herbicides | SYNGENTA LTD | 2014-01-08 | — | — | CN | disclosed |
| EP-2669272-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT OF SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL COMPANY, LIMITED (JP) | 2013-11-28 | — | — | US | disclosed |
| WO-2013159135-A1 | DISPERSION INK | SEPIAX INK TECHNOLOGY GMBH (AT) | 2013-10-31 | — | — | WO | disclosed |
| CN-101855225-A | Tricyclic bridged cyclopentanedione derivatives as weedicide | SYNGENTA LTD | 2010-10-06 | — | — | CN | disclosed |
| EP-2185564-A2 | TRICYCLIC BRIDGED CYCLOPENTANEDIONE DERIVATIVES AS HERBICIDES | Syngenta Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| EP-2185539-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| WO-2009018656-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019005-A2 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317065-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | ALOX5 309/4885PGK1 2445/4885GRM5 694/4885 |
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | ALOX5 1597/4885PGK1 700/4885GRM5 874/4885 |
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | PTGES2, PTGS2, PTGES | ALOX5 18/4885PGK1 271/4885GRM5 1455/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | ALOX5 1795/4885PGK1 701/4885GRM5 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.